Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers

British Journal of Cancer

Volumn 89, Issue 2, 2003, Pages 320-326

  Chang, Y L ^a   Wu, C T ^a   Shih, J Y ^a   Lee, Y C ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE   (Taiwan)

Author keywords

Fhit; Immunohistochemistry; Lung cancers; p53

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; SQUAMOUS CELL CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0043123001     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601041     Document Type: Article

References (30)

1. Burke L, Khan MA, Freedman AN, Gemna A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC (1998) Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 58: 2533-2536
2. Caamano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szanto ATP (1991) Detection of p53 in primary lung tumors and non-small cell lung carcinoma cell lines. Am J Pathol 139: 839-845
3. Campiglio M, Pekarsky Y, Menard S, Tagliabbue E, Pilotti S, Croce CM (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59: 3866-3869
4. Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, Soler M, Stulz P, Mihatsch MJ, Gudat F (1996) Nuclear p53 overexpression in an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 178: 53-58
5. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430-432
6. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD (1997) FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT CDNA splicing aberrations. Cancer Res 57: 2256-2267
7. Fontanini G, Vignati S, Bigini D, Merlo GR, Ribecchini A, Angeletti CA, Basolo F, Pingitore R, Bevilacqua G (1994) Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol 174: 23-31
8. Garinis GA, Gorgoulis VG, mariatos G, Zacharatos P, Kotsinas A, Liloglou T, Foukas P, Kanavaros P, Kastrinakis NG, Vassilakopoulos T, Vogiatzi T, Field JK, Kittas C (2001) Association of ailelic loss at the FHIT locus and p53 alterations with tumor kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J Pathol 193: 55-65
9. Geradts J, Fong KM, Zimmerman PV, Minna JD (2000) Loss of FHIT expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. British J Cancer 82: 1191-1197
10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
11. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Munoz N, Bosch FX, Shah K, Cho KR (1997) Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 57: 4692-4698
12. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K, Croce CM (1997) Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 94: 14584-14589
13. Lee YC, Chang YL, Luh SP, Lee JM, Chen JS (1999) Significance of p53 and Rb protein expression in surgically treated non-small cell lung cancers. Ann Thorac Surg 68: 343-348
14. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL (2002) The significance of E-cadherin and α-, β-, and γ-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 123: 502-506
15. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453-456
16. Marchetti A, Buttita F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R (1993) p53 alteration in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53: 2846-2851
17. Marchetti A, Pellegrini S, Sozzi G, Bertacca G, Gaeta P, Buttitta F, Carnicelli V, Griseri P, Chella A, Angeletti CA, Pierotti M, Bevilacqua G (1998) Genetic analysis of lung tumors of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. J Cancer 78: 73-78
18. Mountain C (1986) A new international staging system for lung cancer. Chest 89, (Suppl) 225-233
19. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597
20. Passlick B, Izbicki JR, Haussinger K, Thetter O, Pantel K (1995) Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Cardiovasc Surg 109: 1205-1211
21. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K (1997) Replacement of FHIT in cancer cells suppressed tumorigenicity. Proc Natl Acad Sci USA 94: 13771-13776
22. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA (1992) Deletions of 17p and p53 mutations in preneoplastic lesions of the lung cancer. Cancer Res 52: 6079-6082
23. Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttita F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Chella A, Angeletti CA, Pastorino U, Huebner K, Bevilaqua G, Pilotti S, Croce CM, Pierotti MA (1997a) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121-2123
24. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pierotti MA (1997b) Absence of FHIT protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 57: 5207-5212
25. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J (1998) Clinicopathological significance of FHIT protein expression in stage I non-small cell lung carcinoma. Cancer Res 58: 5478-5483
26. Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers HR, Visser S, Rodenhuis S (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int J Cancer 64: 83-91
27. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T (1996) Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 56: 5579-5582
28. Yokota J, Sugimura T (1993) Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J 7: 920-925
29. Zambetti GP, Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865
30. Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A (2001) Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84: 226-231